Introduction
============

Androgens such as testosterone are ligands that bind and activate nuclear androgen receptors through deoxyribonucleic acid (DNA) genomic mechanisms[@b1-jen-10-2016-059] or alter neuron function through nongenomic interactions.[@b2-jen-10-2016-059] Testosterone is an endogenous hormone and also a drug of abuse.[@b3-jen-10-2016-059] It is a potent sex steroid produced by the testes in males and a precursor to estrogen synthesis from the ovary in females. In common with all androgens, testosterone has androgenic (masculinizing) and anabolic (muscle building) effects; hence, androgens are collectively known as anabolic androgenic steroids (AASs).

There is an increasing prevalence in the use of testosterone in hormone replacement therapy in elderly men who are predisposed to age-dependent testosterone deficiency due to decreasing testosterone levels associated with debility and reductions in total testosterone with normal aging.[@b4-jen-10-2016-059] The use and abuse of androgenic steroids in adolescents is also increasing rapidly;[@b5-jen-10-2016-059] testosterone in this age group is used largely for enhancement of physical appearance and athletic performance.[@b6-jen-10-2016-059] However, with repeated use of AASs, individual psyche and behavior seem to be strongly affected, with noticeable induction of aggressive behaviors and hostility. Mood disturbances such as depression and hypomania are also documented.[@b7-jen-10-2016-059] Abuse of AASs is a potential global epidemic. According to Sagoe et al, the global lifetime prevalence rate of AAS use is 3.3%, with nonmedical use of AASs fast becoming a public health issue of deep concern.[@b8-jen-10-2016-059] An emerging increase in use of testosterone in young, gonadally intact men in addition to older gonad-deficient men implies a new area of focus for exogenous testosterone research. In addition, more effort needs to be put into studying age-related differences in response to testosterone administration.

Over the years however, extensive research has been conducted on the behavioral consequences of testosterone administration[@b9-jen-10-2016-059],[@b10-jen-10-2016-059] in rodents,[@b11-jen-10-2016-059] nonrodents,[@b12-jen-10-2016-059]--[@b15-jen-10-2016-059] and gonadally intact[@b16-jen-10-2016-059],[@b17-jen-10-2016-059] and gonadectomized animals.[@b17-jen-10-2016-059],[@b18-jen-10-2016-059] Numerous researchers have also studied the effects of either endogenous or exogenous testosterone on various behavioral paradigms such as[@b16-jen-10-2016-059],[@b18-jen-10-2016-059]--[@b24-jen-10-2016-059] sexual behaviors,[@b25-jen-10-2016-059]--[@b27-jen-10-2016-059] obesity or lipid profile,[@b28-jen-10-2016-059],[@b29-jen-10-2016-059] and gender differences.[@b30-jen-10-2016-059]--[@b32-jen-10-2016-059] With regard to age-related difference in testosterone effects, Chambers et al[@b27-jen-10-2016-059] studied the effects of brain androgen binding/metabolism, testosterone, and sexual behavior in intact and gonadectomized old and young male Fischer 344 rats and reported significant differences in sexual behaviors but no significant difference in testosterone effects on aromatase activity. Laroche et al[@b33-jen-10-2016-059] studied how shipping during the prepubertal period or adulthood influenced steroid hormone response in male and female mice and concluded that a reduction in behavioral response to exogenous testosterone administration is seen in prepubertal mice compared to adult mice, irrespective of gender.

Most of the studies conducted dealt with effects of either prenatal or prepubertal testosterone administration on adult behaviors; however, a dearth of literature exists in relation to the effect of exogenous testosterone administration (in two separate age groups) on novelty-induced behaviors, emotionality, and spatial working memory in mice. The rationale for this study is the need for a better understanding of the behavioral changes that accompany testosterone *supplementation* at physiologic (\<3 mg/kg/day) and supraphysiologic doses (\>3 mg/kg/day)[@b34-jen-10-2016-059] in gonadally intact animals. We believe that gonadally intact animals model a significant subset of testosterone users in real life. Over the years, research had concentrated on the effects of exogenous testosterone post-gonadectomy; however, many testosterone users are gonadally intact. In this study, we investigated the effect of age, testosterone administration, and their interactions in gonadally intact prepubertal and aged male mice.

Methods
=======

Drugs
-----

Olive oil (Goya) and testosterone propionate (TP; Hubei-Datong Biochemical Company Limited) were given as i.p. injections of specific doses of testosterone.

Subjects
--------

A total of 220 inbred Swiss albino male mice (Empire Breeders) were used in this study. Mice were housed in plastic cages measuring 41 cm × 31 cm × 26 cm (10 mice in each cage). Housing is a temperature-controlled quarters (22°C--25°C) with 12 hours of light daily. Mice had free access to food and water, except during the behavioral tests. All procedures were conducted in accordance with the approved institutional protocols and within the provisions for animal care and use prescribed in the scientific procedures on living animals, European Council Directive (EU 2010/63).

Experimental method
-------------------

The 220 Swiss albino male mice were divided into two main age-related (prepubertal \[postnatal day (PND) 29\] and aged \[18 months old\]) groups, with 110 mice in each group. Mice in each age-related group were randomly divided into three groups of 10 animals each for the open-field test (30), four groups of 10 animals each for the cognition tests (40), and four groups of 10 animals each for the anxiety-related test (40). Control groups received i.p. injection of vehicle (olive oil), test groups received doses of TP (2.5 and 5.0 mg/kg/day) daily for a period of 21 days, while animals in the fourth group received a standard drug (diazepam at 0.5 mg/kg for the anxiety test and scopolamine at 1 mg/kg for cognition test). Animals were weighed weekly. Behavioral testing after acute dose was carried out 30 minutes after administration of first dose of vehicle, testosterone, or standard drug, while behavioral testing after subchronic dose was carried out 30 minutes after last dose of vehicle, testosterone, or standard drug. Blood samples were collected from 30 mice (animals used in the open-field test) one day after completion of behavioral tests to assay circulating total testosterone levels. Testosterone or vehicle was administered in the morning, and blood samples were collected two to three hours after completion of behavioral tests. Animals were euthanized using diethyl-ether, and blood was collected via a cardiac puncture.

Behavioral testing
------------------

The behavioral models used were the open-field, Y-maze, radial-arm, and elevated plus maze (EPM). Behavioral tests were conducted in a quiet room between the hours of 8 a.m. and 2 p.m. On each of the test days, mice were transported in their home cages to the testing room and allowed 30 minutes to acclimatize before testing; for all behavioral tests, at least 5 minutes was allowed between testing each individual animal to ensure the maze was completely dry and residual odor of ethanol had been dispersed. At the beginning of the behavioral tests, each animal was placed in the apparatus, and its behavior was videotaped for subsequent analysis. After testing, each mouse was removed from the maze and returned to its home cage, and all interior surfaces were cleaned thoroughly with 70% ethanol and then wiped dry to remove any trace of odor.

### Open field

Novelty-induced behaviors were recorded in the open field (horizontal locomotion \[line crossing\], rearing, and grooming) over a 20-minute period.[@b35-jen-10-2016-059] The open-field box is a rectangular arena comprised of a hard floor measuring 36 cm × 36 cm × 26 cm and made of white-painted wood with its floor divided by permanent red markings into 16 equal squares. The mice were placed in the center of the field and covered by a small dome that was then removed at the beginning of video recording of their activities.

### Spatial memory test

Spontaneous alternation (a measure of spatial working memory) was measured using a Y-maze made up of three equally spaced arms (120°, 41 cm long, and 15 cm high). Each mouse was placed in one of the arm compartments and allowed to move freely until its tail completely entered another arm. An alternation is defined as entry into all three arms consecutively, and the number of maximum spontaneous alternations is the total number of arms entered minus two. The percentage alternation is calculated as (actual alternations/maximum alternations) × 100.[@b36-jen-10-2016-059]

Working memory in the radial-arm maze was measured as sequential arm entries before error. The apparatus is made up of eight equidistantly spaced arms, each about 33 cm long, and all radiating from a small circular central platform. Working memory was assessed when the mouse enters each arm a single time. Reentry into the arms would result in a working memory error.[@b36-jen-10-2016-059] For each animal, the Y-maze and radial-arm maze testing each lasted five minutes.

### Anxiety test

Anxiety-related behaviors (time spent in the open) were measured in the EPM.[@b37-jen-10-2016-059] The EPM is plus shaped, with two open arms measuring 25 cm × 5 cm × 5 cm lying across from each other and perpendicular to two closed arms measuring 25 cm × 5 cm × 16 cm with a center platform (5 cm × 5 cm × 0.5 cm). The closed arms are enclosed by two high walls (16 cm), while the open arms have no side walls. Animals are placed in the central platform facing the closed arm and behaviors recorded for five minutes. The observer retired behind a screen to be obscured from the mouse's view. The criterion for arm visit was considered only when the animal decisively moved all its four limbs into an arm.

### Testosterone assay

Plasma was separated by centrifugation and stored at −20° until assayed. Total serum testosterone was measured using commercially available radioimmunoassay kits (Tianjin Medical & Bioengineering Co., Ltd.), following the manufacturer's instructions. The kits had a lower limit of detection of 0.04 ng/mL, with intra- and interassay coefficients of variation of less than 5%. Mice in the vehicle-administered prepubertal group showed total testosterone levels that were not detectable (below the detection limit for the assay, 0.04 ng/mL); for this group, serum testosterone levels were recorded as 0.04 ng/mL to allow for statistical comparisons.

Statistical analysis
--------------------

Data were analyzed using Chris Rorden's ezANOVA for windows, version 0.98. Hypothesis testing was performed using analysis of variance (ANOVA). All data were first tested for normality and variance homogeneity, prior to statistical analysis. Having been found to be normally distributed and variances homogeneous, we tested the hypothesis that patterns of behaviors exhibited by gonadally intact male mice following administration of testosterone are dependent on age using ANOVA. Multifactorial ANOVA was used to test the effects of three main factors: dose, age (prepubertal vs aged), and duration of administration (acute vs subchronic) on behaviors in the open-field, Y-maze, radial-arm maze, and EPM, while two-factor ANOVA was used to analyze the main effect of dose and age on markers of blood testosterone levels. Tukey's honest significant difference test was used for within- and between-group comparisons. Results are expressed as mean ± standard error of mean (SEM), *P* values less than 0.05 were considered statistically significant.

Results
=======

Effect of TP on body weight
---------------------------

[Figure 1](#f1-jen-10-2016-059){ref-type="fig"} shows the effect of TP on body weight. Effect was measured as percentage change in body weight and was defined as the difference between the final and initial body weights divided by initial weight multiplied by 100. Two-factor ANOVA revealed a significant main effect of testosterone dose (*F*(2,54) = 286, *P* \< 0.001), age of mice (*F*(1,54) = 4503, *P* \< 0.001), and very strong interactions between testosterone dose × age (*F*(2,54) = 489, *P* \< 0.001). Pairwise comparisons of the effects of age (prepubertal vs aged) on weight revealed that prepubertal mice gained weight significantly compared to aged mice, following administration of either vehicle or testosterone.

Pairwise comparisons of testosterone dose against vehicle revealed a significant increase in weight in prepubertal mice at 2.5 mg/kg of TP (*t*(18) = 13.94, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 29.43, *P* \< 0.001), while in aged mice, increase in body weight was significantly lesser at 5 mg/kg (*t*(18) = 7.07, *P* \< 0.001) compared to corresponding vehicle-treated groups. At 2.5 mg/kg, no significant difference was seen.

Effect of TP on novelty-induced behaviors
-----------------------------------------

[Figures 2](#f2-jen-10-2016-059){ref-type="fig"}[](#f3-jen-10-2016-059){ref-type="fig"}--[4](#f4-jen-10-2016-059){ref-type="fig"} show the effects of TP on horizontal locomotion, rearing, and grooming, respectively. MANOVA with TP dose, age, and duration of administration (acute behavioral test vs subchronic behavioral tests) as main factors revealed a significant main effect of TP dose (*F*(2,108) = 211, *P* \< 0.001), duration of administration (*F*(1,108) = 1418, *P* \< 0.001), and age (*F*(1,108) = 760, *P* \< 0.001), with strong interactions between testosterone dose × duration of administration (*F*(2,108) = 292, *P* \< 0.001), TP dose × age (*F*(2,108) = 55.8, *P* \< 0.001), duration of administration × age (*F*(1,108) = 2832, *P* \< 0.001), and TP × duration of administration × age (*F*(2,108) = 966, *P* \< 0.001).

Pairwise comparisons of testosterone dose against vehicle following behavioral tests conducted after first dose (hereafter referred to as acute behavioral tests) of either vehicle or TP revealed a significant increase in horizontal locomotion at 2.5 mg/kg of TP (*t*(18) = 43.92, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 36.54, *P* \< 0.001) in prepubertal mice and a significant reduction at 2.5 mg/kg of TP (*t*(18) = 6.88, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 9.07, *P* \< 0.001) in aged mice compared to corresponding vehicle groups. Tests conducted after last dose of vehicle or testosterone (hereafter referred to as subchronic behavioral tests) revealed a significant decrease in locomotor activity at 2.5 mg/kg of TP (*t*(18) = 43.66, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 8.67, *P* \< 0.001) in prepubertal mice and a significant increase at 2.5 mg/kg of TP (*t*(18) = 34.23, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 10.15, *P* \< 0.001) in aged mice compared to corresponding vehicle-treated groups.

Pairwise comparison of age-related effects revealed a significant increase in locomotor activity at 2.5 mg/kg of TP (*t*(18) = 60.67, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 37.64, *P* \< 0.001) in prepubertal mice compared to aged mice with acute behavioral tests and a significant decrease at 2.5 mg/kg of TP (*t*(18) = 56.43, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 4.63, *P* \< 0.002) with subchronic behavioral tests; however, there was no significant difference in the groups administered vehicle in either prepubertal or aged animals. Comparison of effects due to duration of administration (acute behavioral test vs subchronic behavioral tests) revealed a significant increase in locomotor activity at 2.5 mg/kg of TP (*t*(18) = 75.11, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 27.53, *P* \< 0.001; acute vs subchronic behavioral tests) in prepubertal mice and a significant decrease in locomotor activity at 2.5 mg/kg of TP (*t*(18) = 37.16, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 2.16, *P* \< 0.045; acute vs subchronic behavioral tests) in aged mice.

[Figure 3](#f3-jen-10-2016-059){ref-type="fig"} shows the effect of TP on rearing activity. MANOVA revealed a significant main effect of TP dose (*F*(2,108) = 18.6, *P* \< 0.001), duration of administration (*F*(1,108) = 78.9, *P* \< 0.001), and age (*F*(1,108) = 41.4, *P* \< 0.001), with strong interactions between TP × duration of administration (*F*(2,108) = 13.4, *P* \< 0.006), TP dose × age (*F*(2,108) = 121, *P* \< 0.001), duration of administration × age (*F*(1,108) = 35.6, *P* \< 0.001), and TP dose × duration of administration × age (*F*(2,108) = 67.1, *P* \< 0.001). Pairwise comparison of testosterone dose against vehicle following behavioral tests conducted after first dose (acute behavioral tests) of either vehicle or TP revealed a significant increase in rearing at 2.5 (*t*(18) = 25.92, *P* \< 0.001) and 5 mg/kg (*t*(18) = 26.40, *P* \< 0.001) in prepubertal mice and a decrease at 2.5 (*t*(18) = 10.82, *P* \< 0.001) and 5 mg/kg (*t*(18) = 3.30, *P* \< 0.004) in aged mice compared to corresponding vehicle-treated groups. Tests conducted after last dose (subchronic behavioral tests) of vehicle or TP showed an decrease in rearing at 2.5 (*t*(18) = 31.68, *P* \< 0.001) and an increase at 5 mg/kg (*t*(18) = 41.79, *P* \< 0.001) in prepubertal mice and a decrease at 2.5 (*t*(18) = 5.33, *P* \< 0.005) and 5 mg/kg (*t*(18) = 3.41, *P* \< 0.031) in aged mice compared to corresponding vehicle groups.

Comparison of age-related effects revealed a significant increase in rearing activity at 2.5 (*t*(18) = 18.38, *P* \< 0.001) and 5 mg/kg (*t*(18) = 13.83, *P* \< 0.001) of TP in prepubertal mice compared to aged mice with acute behavioral tests and a significant decrease at 2.5 (*t*(18) = 8.31, *P* \< 0.001) and an increase at 5 mg/kg (*t*(18) = 43.31, *P* \< 0.001) in prepubertal compared to aged mice following subchronic behavioral tests; however, there was no significant difference in the groups administered vehicle in either prepubertal or aged animals. Comparison of effects due to duration of administration (acute behavioral test vs subchronic behavioral tests) revealed a significant increase in rearing activity at 2.5 (*t*(18) = 19.61, *P* \< 0.001) and 5 mg/kg (*t*(18) = 11.67, *P* \< 0.001; acute vs subchronic behavioral tests) in prepubertal mice. A significant decrease in rearing activity at 2.5 (*t*(18) = 8.48, *P* \< 0.001) and an increase at 5 mg/kg (*t*(18) = 16.22, *P* \< 0.001; acute vs subchronic behavioral tests) was seen in aged mice.

[Figure 4](#f4-jen-10-2016-059){ref-type="fig"} shows the effect of TP on grooming behavior. MANOVA revealed a significant main effect of TP dose (*F*(2,108) = 4253, *P* \< 0.001), duration of administration (*F*(1,108) = 202, *P* \< 0.001), and age (*F*(1,108) = 1378, *P* \< 0.001), with strong interactions between TP dose × duration of administration (*F*(2,108) = 246, *P* \< 0.006), TP dose × age (*F*(2,108) = 4127, *P* \< 0.001), duration of administration × age (*F*(1,108) = 938, *P* \< 0.001), and TP dose × duration of administration × age (*F*(2,108) = 210, *P* \< 0.001). Pairwise comparisons of the effect of testosterone dose against vehicle in behavioral tests after first dose (acute behavioral tests) of either vehicle or TP revealed a significant decrease in grooming at 2.5 (*t*(18) = 70.94, *P* \< 0.001) and at 5 mg/kg (*t*(18) = 94.04, *P* \< 0.001) in prepubertal mice and an increase at 2.5 (*t*(18) = 8.58, *P* \< 0.001) and 5 mg/kg (*t*(18) = 11.31, *P* \< 0.001) in aged mice compared to corresponding vehicle-treated groups. Tests conducted after the last dose (subchronic behavioral tests) of either vehicle or TP revealed a significant decrease in grooming at 2.5 (*t*(18) = 72.17, *P* \< 0.001) and 5 mg/kg (*t*(18) = 77.25, *P* \< 0.001) in prepubertal mice and at 2.5 mg/kg in aged mice compared to corresponding vehicle-treated groups. However, in aged mice at 5 mg/kg, no significant difference was seen.

Comparison of age-related effects revealed a significant increase in grooming in prepubertal compared to aged mice at baseline (vehicle) following both acute and subchronic behavioral tests. Administration of testosterone decreased grooming at 2.5 (*t*(18) = 23.67, *P* \< 0.001) and 5 mg/kg (*t*(18) = 41.00, *P* \< 0.001) in prepubertal mice compared to aged mice with acute behavioral tests and resulted in a significant increase at 2.5 (*t*(18) = 22.56, *P* \< 0.001) and a decrease at 5 mg/kg (*t*(18) = 4.74, *P* \< 0.002) in prepubertal compared to aged mice with subchronic behavioral tests. The significant difference seen previously is also reflected in a significant mean absolute difference measured when grooming scores of vehicle-treated prepubertal or aged mice were subtracted from corresponding age-matched grooming scores following TP at either 2.5 mg/kg (22.54 prepubertal vs −3 aged) or 5 mg/kg (26.27 prepubertal vs −4.45 aged) following acute behavioral tests and at 2.5 mg/kg (22.72 prepubertal vs 8.36 aged) or 5 mg/kg (25.10 prepubertal vs 0.55 aged) with subchronic behavioral tests. Comparison of effects due to duration of administration (acute behavioral test vs subchronic behavioral tests) revealed a significant decrease in grooming at 5 mg/kg (*t*(18) = 29.00, *P* \< 0.001; acute vs subchronic behavioral tests) in prepubertal mice and a significant increase in grooming at 2.5 (*t*(18) = 51.51, *P* \< 0.001) and 5 mg/kg (*t*(18) = 17.90, *P* \< 0.001; acute vs subchronic behavioral tests) in aged mice.

Effect of TP on spatial working memory tasks
--------------------------------------------

[Figures 5](#f5-jen-10-2016-059){ref-type="fig"} shows the effects of TP on arm entry before first error in the radial-arm maze. MANOVA revealed a significant main effect of TP dose (*F*(3,144) = 278, *P* \< 0.001), duration of administration (*F*(1,144) = 11.8, *P* \< 0.001), and age (*F*(1,144) = 11.8, *P* \< 0.001), with strong interactions between TP dose × duration of administration (*F*(3,144) = 12.7, *P* \< 0.001), TP dose × age (*F*(3,144) = 43.00, *P* \< 0.001), and TP dose × duration of administration × age (*F*(3,144) = 44.5 *P* \< 0.001), with no significant interaction of duration of administration × age (*F*(1,144) = 0.240, *P* \< 0.626). Pairwise comparisons of the effect of testosterone dose against vehicle in behavioral tests conducted after first dose (acute behavioral tests) of vehicle, scopolamine control, or TP revealed significant decrease in radial-arm maze memory task scores (measured as number of arm entry before first error) in groups administered scopolamine (animal model of memory loss; *t*(18) = 5.69, *P* \< 0.001) and an increase at 2.5 mg/kg (*t*(18) = 8.50, *P* \< 0.001) in prepubertal mice, while in aged mice, there was a significant decrease in the scopolamine control group score (*t*(18) = 3.97, *P* \< 0.001) and a significant increase at 5 mg/kg (*t*(18) = 13.38, *P* \< 0.001) compared to corresponding vehicle groups. At 5 mg/kg (prepubertal) and 2.5 mg/kg (aged), no significant difference was seen. In comparison to scopolamine control however, there was a significant increase in radial-arm maze memory task scores at 2.5 (*t*(18) = 15.29, *P* \< 0.001; *t*(18) = 3.35, *P* \< 0.004) and 5 mg/kg (*t*(18) = 5.30, *P* \< 0.001; *t*(18) = 15.25, *P* \< 0.001) in prepubertal and aged mice, respectively. Tests conducted after last dose (subchronic behavioral tests) of vehicle, scopolamine, or TP revealed a significant decrease in radial-arm maze memory task score in groups administered scopolamine (*t*(18) = 5.66, *P* \< 0.001; *t*(18) = 4.99, *P* \< 0.001) and an increase at 2.5 (*t*(18) = 15.56, *P* \< 0.001; *t*(18) = 6.53, *P* \< 0.001) and 5 mg/kg (*t*(18) = 13.80, *P* \< 0.001; *t*(18) = 5.82, *P* \< 0.001) in both prepubertal and aged mice, respectively. In comparison to scopolamine control, radial-arm memory task scores also increased significantly at 2.5 (*t*(18) = 21.21, *P* \< 0.001; *t*(18) = 15.91, *P* \< 0.001) and 5 mg/kg (*t*(18) = 18.60, *P* \< 0.001; *t*(18) = 12.32, *P* \< 0.001) in both prepubertal and aged mice, respectively. Pairwise comparison of age-related effects revealed a significant increase in radial-arm maze memory task scores at 2.5 mg/kg (*t*(18) = 9.26, *P* \< 0.001) and a decrease at 5 mg/kg (*t*(18) = 17.40, *P* \< 0.001) in prepubertal mice compared to aged mice after acute behavioral tests, and no significant difference seen at any doses of TP after subchronic behavioral tests. There was no significant difference in the groups administered vehicle (baseline) in either prepubertal or aged animals. Comparison of effects due to duration of administration (acute behavioral test vs subchronic behavioral tests) revealed a significant decrease in memory task scores at 5 mg/kg (*t*(18) = 10.61, *P* \< 0.001; acute vs subchronic) in prepubertal mice. A significant decrease in memory task score was seen at 2.5 mg/kg (*t*(18) = 51.51, *P* \< 0.001) and an increase at 5 mg/kg (*t*(18) = 3.39, *P* \< 0.003) in aged mice.

[Figure 6](#f6-jen-10-2016-059){ref-type="fig"} shows the effects of TP on percentage alternation in the Y-maze. MANOVA revealed a significant main effect of TP dose (*F*(3,144) = 1850, *P* \< 0.001), duration of administration (*F*(1,144) = 293, *P* \< 0.001), and age (*F*(1,144) = 309, *P* \< 0.001), with strong interactions between TP dose × duration of administration (*F*(2,144) = 51.8, *P* \< 0.001), TP dose × age (*F*(2,144) = 758, *P* \< 0.001), duration of administration × age (*F*(2,144) = 174, *P* \< 0.001), and TP dose × duration of administration × age (*F*(3,144) = 99.4, *P* \< 0.001). Pairwise comparisons of the effect of testosterone dose and vehicle in behavioral tests conducted after first dose (acute behavioral tests) of vehicle, scopolamine, or TP groups revealed a significant decrease in Y-maze memory task scores (measured as % alternation) in groups administered scopolamine (*t*(18) = 7.17, *P* \< 0.001) and an increase at 2.5 mg/kg of TP (*t*(18) = 4.55, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 19.52, *P* \< 0.001) in prepubertal mice; it also showed a significant decrease at 2.5 (*t*(18) = 49.60, *P* \< 0.001) and 5 mg/kg (*t*(18) = 10.84, *P* \< 0.001) of TP in aged mice compared to respective vehicle administered groups. In comparison to scopolamine control, there was a significant increase in Y-maze memory task scores at 2.5 (*t*(18) = 11.85, *P* \< 0.001; *t*(18) = 25.62, *P* \< 0.001) and 5 mg/kg (*t*(18) = 23.69, *P* \< 0.001; *t*(18) = 33.70, *P* \< 0.001) in both prepubertal and aged mice, respectively. Tests conducted after the last dose (subchronic behavioral tests) of vehicle, scopolamine, or TP revealed a significant decrease in memory task scores in groups administered scopolamine (*t*(18) = 19.40, *P* \< 0.001; *t*(18) = 76.55, *P* \< 0.001) and an increase at 2.5 mg/kg of TP (*t*(18) = 20.44, *P* \< 0.001; *t*(18) = 42.98, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 13.48, *P* \< 0.001; *t*(18) = 24.70, *P* \< 0.001) in pre-pubertal mice and aged mice, respectively, when compared to vehicle. In comparison to scopolamine control however, there was a significant increase in Y-maze memory tasks scores at 2.5 (*t*(18) = 47.84, *P* \< 0.001; *t*(18) = 21.35, *P* \< 0.001) and 5 mg/kg (*t*(18) = 37.93, *P* \< 0.001; *t*(18) = 32.87, *P* \< 0.001) in prepubertal and aged mice, respectively. Pairwise comparison of age-related effects revealed a significant decrease in Y-maze memory tasks at 2.5 (*t*(18) = 7.41, *P* \< 0.001) and 5 mg/kg (*t*(18) = 3.08, *P* \< 0.007) in prepubertal mice compared to aged mice with acute behavioral tests and a significant increase at 2.5 (*t*(18) = 27.26, *P* \< 0.001) and 5 mg/kg (*t*(18) = 4.24, *P* \< 0.001) in prepubertal mice compared to aged mice with subchronic behavioral tests. There was no significant difference in the groups administered vehicle in either prepubertal or aged mice. Comparison of effects due to duration of administration of TP (acute behavioral test vs subchronic behavioral tests) revealed a significant increase in Y-maze memory task scores at 2.5 (*t*(18) = 19.38, *P* \< 0.001) and a decrease at 5 mg/kg (*t*(18) = 9.42, *P* \< 0.001; acute vs subchronic) in prepubertal mice and a significant increase in memory task sores at 2.5 (*t*(18) = 15.59, *P* \< 0.001) and 5 mg/kg (*t*(18) = 13.58, *P* \< 0.003; acute vs subchronic) in aged mice.

Effect of TP on anxiety behavior
--------------------------------

[Figure 7](#f7-jen-10-2016-059){ref-type="fig"} shows the effect of TP on percentage time spent in the open arm of the EPM. MANOVA revealed a significant main effect of TP dose (*F*(3,144) = 21,962, *P* \< 0.001), duration of administration (*F*(1,144) = 1439, *P* \< 0.001), and age (*F*(1,144) = 547, *P* \< 0.001), with strong interactions between TP dose × duration of administration (*F*(2,144) = 712, *P* \< 0.001), TP dose × age (*F*(2,144) = 975, *P* \< 0.001), duration of administration × age (*F*(2,144) = 309, *P* \< 0.001), and TP dose × duration of administration × age (*F*(3,144) = 2015, *P* \< 0.001). Pairwise comparisons of the effect of testosterone and vehicle in behavioral tests carried out after first dose (acute behavioral tests) of vehicle, diazepam, or TP showed a significant increase in percentage open arm time in groups of animals administered diazepam (an animal model of anxiolysis) at (*t*(18) = 90.02, *P* \< 0.001) and following TP at 2.5 (*t*(18) = 35.18, *P* \< 0.001) with a decrease at 5.0 mg/kg (*t*(18) = 5.4, *P* \< 0.001) in prepubertal mice. In aged mice, there was a significant increase in open arm time with diazepam (*t*(18) = 112.75, *P* \< 0.001) and following TP at 5 mg/kg (*t*(18) = 67.10, *P* \< 0.001), at 2.5 mg/kg no significant difference was seen. Tests carried out after last dose (subchronic behavioral tests) of vehicle, diazepam, or TP revealed a significant increase in open arm time in groups administered diazepam (*t*(18) = 127.39, *P* \< 0.001; *t*(18) = 97.94, *P* \< 0.001) and at 2.5 mg/kg (*t*(18) = 5,43, *P* \< 0.001; *t*(18) = 8.79, *P* \< 0.001) of TP in both prepubertal and aged mice, respectively. At 5 mg/kg, there was a significant increase in open arm time for prepubertal mice (*t*(18) = 5.43, *P* \< 0.001) and a decrease for aged mice (*t*(18) = 11.40, *P* \< 0.001). In comparison to diazepam control, open arm time decreased at 2.5 mg/kg (*t*(18) = 73.50, *P* \< 0.001; *t*(18) = 150.43, *P* \< 0.001) and 5 mg/kg (*t*(18) = 105.75, *P* \< 0.001; *t*(18) = 165.22, *P* \< 0.001) in prepubertal and aged mice, respectively, following acute behavioral tests. Following subchronic behavioral tests, open arm time also decreased at 2.5 mg/kg (*t*(18) = 117.22, *P* \< 0.001; *t*(18) = 126.84, *P* \< 0.001) and 5 mg/kg (*t*(18) = 117.22, *P* \< 0.001; *t*(18) = 165.22, *P* \< 0.001) compared to respective diazepam-treated groups. Pairwise comparison of age-related effects revealed a significant increase in percentage time spent in the open arm at 2.5 (*t*(18) = 48.38, *P* \< 0.001; *t*(18) = 15.29, *P* \< 0.001) and a decrease at 5 mg/kg (*t*(18) = 75.89, *P* \< 0.002; *t*(18) = 15.28, *P* \< 0.001) in prepubertal mice compared to aged mice following both acute and subchronic behavioral tests, respectively. There was no significant difference in the groups administered vehicle, either prepubertal or aged. Comparison of effects due to duration of administration (acute behavioral test vs subchronic behavioral tests) revealed a significant increase in open arm time at 2.5 (*t*(18) = 45.17, *P* \< 0.001) and a decrease at 5 mg/kg (*t*(18) = 10.34, *P* \< 0.001; acute vs subchronic tests) in prepubertal mice. A significant decrease in open arm time at 2.5 (*t*(18) = 48.38, *P* \< 0.001) and an increase at 5 mg/kg (*t*(18) = 93.34, *P* \< 0.001; acute vs subchronic tests) was seen in aged mice.

Effect of TP on locomotor activity in the Y-maze, radial-arm maze, and EPM
--------------------------------------------------------------------------

[Figures 8](#f8-jen-10-2016-059){ref-type="fig"}[](#f9-jen-10-2016-059){ref-type="fig"}--[10](#f10-jen-10-2016-059){ref-type="fig"} show the effect of TP on locomotor activity measured as total arm entry in the Y- and radial-arm maze and percentage time spent in the closed arm in the EPM, respectively.

Following exploration in the Y-maze, MANOVA revealed a significant main effect of TP dose (*F*(2,144) = 110.6, *P* \< 0.001), duration of administration (*F*(1,144) = 31.5, *P* \< 0.012), and age (*F*(1,144) = 123.54, *P* \< 0.002), with strong interactions between TP dose × duration of administration (*F*(2,144) = 932, *P* \< 0.001), TP dose × age (*F*(2,108) = 586, *P* \< 0.001), duration of administration × age (*F*(2,144) = 195, *P* \< 0.001), and TP dose × duration of administration × age (*F*(2,144) = 989, *P* \< 0.001). Y-maze total arm entry decreased significantly with administration of scopolamine (*t*(18) = 189.53, *P* \< 0.001; *t*(18) = 178.33, *P* \< 0.001) in both prepubertal and aged mice. In prepubertal mice, Y-maze total arm entry increased significantly at 2.5 mg/kg of TP (*t*(18) = 13.53, *P* \< 0.001) and 5 mg/kg of TP (*t*(18) = 16.11, *P* \< 0.001) and decreased at 2.5 (*t*(18) = 15.52, *P* \< 0.001) and 5.0 mg/kg (*t*(18) = 26.33, *P* \< 0.001) in aged mice compared to respective vehicle-treated groups following acute behavioral tests. With subchronic behavioral tests, arm entry decreased significantly at 2.5 mg/kg (*t*(18) = 24.79, *P* \< 0.001) in aged mice and showed no significant difference at 5 mg/kg in aged mice or any of the doses in prepubertal mice. In comparison to scopolamine control, there was a significant increase in Y-maze total arm entry at 2.5 (*t*(18) = 41.15, *P* \< 0.001; *t*(18) = 65.32, *P* \< 0.001) and 5 mg/kg (*t*(18) = 3.98, *P* \< 0.011; *t*(18) = 73.10, *P* \< 0.001) in both prepubertal and aged mice, respectively, following both acute and subchronic behavioral tests. Pairwise comparisons of the effects of age revealed significant increase at 2.5 (*t*(18) = 18.44, *P* \< 0.001) and 5 mg/kg (*t*(18) = 29.85, *P* \< 0.001) with acute behavioral test and at 2.5 mg/kg (*t*(18) = 12.04, *P* \< 0.001) with subchronic behavioral tests in prepubertal compared to aged mice.

Following exploration in the radial-arm maze, MANOVA revealed a significant main effect of TP dose (*F*(2,144) = 125.00, *P* \< 0.001), duration of administration (*F*(1,144) = 523, *P* \< 0.001), and age (*F*(1,144) = 52.63, *P* \< 0.012), with strong interactions between TP dose × duration of administration (*F*(2,144) = 58.4, *P* \< 0.001), TP dose × age (*F*(2,144) = 156, *P* \< 0.001), duration of administration × age (*F*(2,144) = 75.2, *P* \< 0.001), and TP dose × duration of administration × age (*F*(2,144) = 45.2, *P* \< 0.001). Total arm entry in the radial-arm maze decreased significantly with administration of scopolamine (*t*(18) = 155, *P* \< 0.001; *t*(18) = 162, *P* \< 0.001) in both prepubertal and aged mice. Radial-arm maze total arm entry increased significantly at 2.5 mg/kg (*t*(18) = 33.98, *P* \< 0.001) and decreased at 5.0 mg/kg (*t*(18) = 14.00, *P* \< 0.011) with acute behavioral tests in prepubertal mice while with aged mice, arm entry decreased at 2.5 (*t*(18) = 25.64, *P* \< 0.001) and 5 mg/kg (*t*(18) = 38.01, *P* \< 0.001). With subchronic behavioral tests, arm entry increased at 2.5 and 5 mg/kg (*t*(18) = 26.30, *P* \< 0.001; *t*(18) = 42.43, *P* \< 0.001), respectively, in prepubertal mice and decreased at 2.5 and 5 mg/kg (*t*(18) = 21.86, *P* \< 0.001; *t*(18) = 45.12, *P* \< 0.001), respectively, in aged mice. In comparison to scopolamine control, there was a significant increase in radial-arm maze total arm entry at 2.5 (*t*(18) = 55.25, *P* \< 0.001; *t*(18) = 25.12, *P* \< 0.001) and 5 mg/kg (*t*(18) = 54.00, *P* \< 0.001; *t*(18) = 13.66, *P* \< 0.001) in both prepubertal and aged mice, respectively, following both acute and subchronic behavioral tests. Pairwise comparisons of the effect of age revealed a significant increase in radial-arm maze total arm entry at 2.5 mg/kg (*t*(18) = 23.40, *P* \< 0.001) and a decrease at 5.0 mg/kg (*t*(18) = 19.00, *P* \< 0.001) following acute behavioral tests; with subchronic test, there was a significant increase at 2.5 and 5 mg/kg (*t*(18) = 14.33, *P* \< 0.001 *t*(18) = 14.42, *P* \< 0.001), respectively, in prepubertal compared to aged mice.

Following 5 minutes of exploration in the EPM, MANOVA revealed significant main effects of TP dose (*F*(3,144) = 21,007, *P* \< 0.001), duration of administration (*F*(1,144) = 470, *P* \< 0.011), and age (*F*(1,144) = 28.5, *P* \< 0.001), with strong interactions between TP dose × duration of administration (*F*(3,144) = 165, *P* \< 0.001), TP dose × age (*F*(3,144) = 585, *P* \< 0.001), and TP dose × duration of administration × age (*F*(3,144) = 621 *P* \< 0.001), with no significant interaction of duration of administration × age (*F*(1,144) = 5.8, *P* \< 0.677). Percentage time in the closed arm of the EPM revealed a significant decrease following administration of diazepam (*t*(18) = 176.63, *P* \< 0.001; *t*(18) = 82.60, *P* \< 0.001) in prepubertal and aged mice, respectively. Closed arm time also increase at 2.5 (*t*(18) = 40.76, *P* \< 0.001) and 5 mg/kg (*t*(18) = 12.97, *P* \< 0.001) in prepubertal mice and at 5.0 mg/kg (*t*(18) = 35.55, *P* \< 0.001) in aged mice with acute behavioral tests. Following subchronic behavioral tests, percentage time in the closed arm decreased in the groups administered diazepam (*t*(18) = 163.29, *P* \< 0.001; *t*(18) = 95.69, *P* \< 0.001) in prepubertal and aged mice, respectively, while no significant difference was seen at either doses of TP in either prepubertal or aged mice compared to respective vehicle-treated groups. In comparison to diazepam-treated groups, closed arm time increased at 2.5 mg/kg (*t*(18) = 123.04, *P* \< 0.001; *t*(18) = 68.25, *P* \< 0.001) and 5 mg/kg (*t*(18) = 165.75, *P* \< 0.001; *t*(18) = 92.30, *P* \< 0.001) in prepubertal and aged mice, respectively, following acute behavioral tests. Following subchronic behavioral tests, closed arm time also increased at 2.5 mg/kg (*t*(18) = 106.37, *P* \< 0.001; *t*(18) = 109.34, *P* \< 0.001) and 5 mg/kg (*t*(18) = 119.144, *P* \< 0.001; *t*(18) = 155.39, *P* \< 0.001) compared to respective diazepam-treated groups. Pairwise comparison of the effect of age showed no significant difference between prepubertal and aged mice at either of the doses.

Effect of TP on serum testosterone levels
-----------------------------------------

[Figure 11](#f11-jen-10-2016-059){ref-type="fig"} shows the effect of subchronic intraperitoneal injection of TP on serum testosterone levels in prepubertal and aged mice. Two-factor ANOVA revealed a significant main effect of testosterone dose (*F*(2,18) = 319, *P* \< 0.001), age (*F*(1,18) = 91.0, *P* \< 0.001), and testosterone dose vs age interaction (*F*(2,18) = 22.6, *P* \< 0.001). Serum testosterone levels increased (*F*(2,18) = 319, *P* \< 0.001) at both doses of TP in both prepubertal and aged mice. Comparing effects seen in prepubertal to aged mice revealed significant increase at 2.5 mg/kg (*t*(6) = 8.25, *P* \< 0.002) and 5.0 mg/kg (*t*(6) = 5.99, *P* \< 0.010) in aged mice compared to prepubertal mice.

Discussion
==========

Endogenous or exogenous testosterone influences brain behavior and chemistry through mechanisms that are both due to its organizational and activational effects.[@b38-jen-10-2016-059] Concerning its effects, a number of human and animal studies have been published, with several conflicting and puzzling results largely due to variability in dosing, route of administration, state of the gonads, gender, and timing, all of which could considerably alter outcome.[@b38-jen-10-2016-059] We set out to investigate the effects exogenous testosterone in gonadally-intact prepubertal and aged male mice with a view to testing the hypothesis that aging modulates the influence of exogenous testosterone on neurobehavior and serum testosterone levels.

The results of this study revealed alterations in behavioral response of gonadally intact male mice to i.p. injection of TP, which were influenced not only by age (prepubertal vs aged) but also by duration of administration (effects seen when behavioral tests were conducted after 1st dose compared to after the 21st dose of TP \[acute versus subchronic\]). The prepubertal period in male rodents extend from PNDs 28 to 70.[@b39-jen-10-2016-059],[@b40-jen-10-2016-059] This period however can be characterized using varying physiological parameters, such as physical features, levels of sex steroid, the attainment of sexual maturity, and reproductive capability.[@b41-jen-10-2016-059] These variations make comparisons of research results difficult.

In this study, all animals administered TP gained weight over the 21-day period, although prepubertal mice gained more weight than aged mice at both doses. Studies have shown that administration of androgenic steroids could result in weight gain.[@b42-jen-10-2016-059],[@b43-jen-10-2016-059] The results seen in aged mice corroborate the results by Davies et al,[@b44-jen-10-2016-059] who reported a decrease in weight in male obese Zucker rats following testosterone supplementation. Several human studies have also reported weight loss in elderly men on hormone replacement therapy.[@b45-jen-10-2016-059] Testosterone therapy has been associated with weight reduction and increase in lean body mass,[@b46-jen-10-2016-059],[@b47-jen-10-2016-059] in obese elderly men with primary hypogonadism on hormone replacement therapy. Weight changes seen in prepubertal mice could be attributable to prepubertal growth spurts.[@b48-jen-10-2016-059] In aged mice, a decrease in total body fat may be a plausible explanation for the changes seen, as an inverse association has been described between levels of testosterone and accumulation of body fat.[@b49-jen-10-2016-059],[@b50-jen-10-2016-059]

Testosterone (endogenous or exogenous) has been reported to exert several behavioral traits in both human and animal studies,[@b51-jen-10-2016-059] and these effects are mediated not only through the androgen or estrogen receptors but also through rapid nongenomic effects.[@b52-jen-10-2016-059] In this study, administration of testosterone resulted in increase in horizontal locomotion and rearing in prepubertal mice with acute administration and a decrease with repeated administration, while in aged mice, the reverse was the case. Grooming behavior however showed a decrease in prepubertal mice and an increase in aged mice with acute administration, while with repeated administration, it decreased in both prepubertal and aged mice. Results of behavioral tests after acute TP administration in prepubertal mice and repeated administration of TP in aged mice point to cerebral cortical stimulation. It was also observed that repeated administration of testosterone in prepubertal rats had inhibitory effects on cerebral cortical stimulation. Central excitatory effect seen in prepubertal mice after acute administration could have been mediated via glutamatergic and dopaminergic systems. A few studies have indicated that testosterone supplementation particularly within the adolescence period may regulate dopamine neurotransmission.[@b53-jen-10-2016-059] Purves-Tyson[@b54-jen-10-2016-059] reported that exogenous testosterone during adolescence (between PNDs 45 and 60) in male rats increased dopamine synthesis and stimulated expression of dopamine receptor 2 messenger RNA (DR2 mRNA) in the midbrain. Dopaminergic transmission in the nucleus accumbens may have increased with testosterone supplementation since increase in dopaminergic transmission in the nucleus accumbens is associated with locomotor hyperactivity and increases in the caudate nucleus with increased rearing activity.[@b55-jen-10-2016-059] Results of repeated administration however suggests possible upregulation of the Gamma aminobutyric acid (GABA) systems, which could be direct, as seen when testosterone supplementation in postnatal female rats resulted in upregulation of α2 subunit of the GABA receptor subunits in the cerebral cortex,[@b56-jen-10-2016-059] or indirect via the effect of serotonin receptor in the amygdala, which have been shown to potentiate GABAergic inhibitory interneurons, resulting in central inhibition of neuronal activity.[@b57-jen-10-2016-059] However, how TP specifically interacts with dopaminergic, glutamatergic, and serotonergic systems to modify novelty-induced behaviors in rodents is still a source of continuous research.

Testosterone has been reported to influence spatial cognition in male rats,[@b58-jen-10-2016-059],[@b59-jen-10-2016-059] especially in studies that have been modeled using reward or task-motivated paradigms, however, spatial-working memory model used in our study capitalizes on the propensity of mice to navigate toward novel spatial environments and remember where they have last visited. Numerous studies have documented the gender-related effects of testosterone on memory in rodents.[@b23-jen-10-2016-059],[@b58-jen-10-2016-059] Some of these studies involved spatial memory tasks that compared the performance of castrated male animals given TP to that of females, with many concluding that males tend to outperform females.[@b60-jen-10-2016-059],[@b61-jen-10-2016-059] Few studies have however tried to evaluate age-related differences in response among males. A number of human and rodent studies have reported that testosterone supplementation improves spatial working memory,[@b62-jen-10-2016-059],[@b63-jen-10-2016-059] while some reported no effect.[@b23-jen-10-2016-059] In this study, working memory in the radial-arm maze increased in both prepubertal and aged mice, with prepubertal mice performing better than aged mice at the lower dose and aged mice performing better at the higher dose, this effect was sustained with repeated administration. Y-maze spatial working memory increased in prepubertal mice and showed no significant improvements in aged mice. Our results corroborate those by Spritzer et al,[@b50-jen-10-2016-059] where a disparity in working memory effect of testosterone is seen with respect to model used, pointing to the possibility of task-dependent response with testosterone. Variations in accuracy of working memory measurement by the two tasks may also be responsible, although it is accepted that radial-arm reentry errors are a better index of working memory; other reasons may include age-related differences in receptor modulation effects of testosterone and its metabolites.[@b60-jen-10-2016-059] Many of the models that have been used to study spatial memory including the radial-arm maze and Y-maze rely heavily on hippocampal function.[@b15-jen-10-2016-059],[@b62-jen-10-2016-059] Though the mechanisms underlying sex steroid effects on spatial memory are not entirely clear, both exogenous estradiol and testosterone have been shown to alter pyramidal spine density and connectivity in the cornus ammonis 1 region and possible cornus ammonis 3 in the hippocampus.[@b15-jen-10-2016-059],[@b62-jen-10-2016-059] However, higher endogenous testosterone levels have been associated with increased pyramidal cell activity in the amygdala and also with improved memory.[@b64-jen-10-2016-059]

Anxiety is reported to be the most sensitive behavioral response to testosterone.[@b35-jen-10-2016-059] In this study, dose-related anxiolysis was noticed in both prepubertal and aged mice, although the anxiolytic effect reported was significantly less than that following administration of diazepam. Repeated administration of testosterone showed mixed responses. A number of researchers have investigated the effects of endogenous and exogenous testosterone on anxiety-related behaviors in rodents and humans,[@b52-jen-10-2016-059],[@b58-jen-10-2016-059],[@b65-jen-10-2016-059]--[@b69-jen-10-2016-059] most of these studies reported anxiolytic effects of testosterone. Aikey et al[@b69-jen-10-2016-059] reported anxiolysis in male mice following endogenous and exogenous testosterone in the EPM, although this effect was dose dependent. Fernandez-Guasti and Martinez-Mota[@b68-jen-10-2016-059] also reported anxiolysis, this time in the marble-burying behavior test, while Van-Honk et al[@b67-jen-10-2016-059] reported anxiolytic effects of testosterone administration in women. The results obtained in the previous studies are similar to what we observed in our study, a dose-related anxiolytic effect following acute behavioral tests. This result also corroborates what was reported by Frye et al,[@b66-jen-10-2016-059] who observed anxiolytic effects in a number of anxiety-related behavioral paradigms following acute administration of testosterone in aged intact, male mice. Overall, with continuous administration of TP, mice spent less time in the open arm irrespective of their age. Anxiogenic effect of nandrolone, a synthetic testosterone derivative, has been reported following chronic administration,[@b57-jen-10-2016-059],[@b70-jen-10-2016-059] while some other studies have reported either no response or anxiolytic effects in some behavioral paradigms, which are not replicated in others.[@b51-jen-10-2016-059] Though testosterone may have the ability to reduce anxiety or increase it, its effects and mechanisms are still being studied, and different mechanisms are being proposed and investigated.

From our study, effects of testosterone on anxiety behaviors are modulated by age, dose of testosterone, and duration of administration. Possible mechanisms of testosterone action on anxiety (in our opinion) could be both genomic and nongenomic. The acute anxiolytic effect seen is possible through rapid nongenomic mechanisms, while the anxiogenic effects seen with continuous administration is possible through genomic mechanisms. Earlier studies have shown that the anxiogenic or anxiolytic effects of testosterone could be mediated via androgen or estrogen receptors and also via rapid nongenomic effects or via interactions with GABA benzodiazepines receptors.[@b57-jen-10-2016-059],[@b69-jen-10-2016-059] Hodosy et al[@b51-jen-10-2016-059] were of the opinion that both exogenous and endogenous testosterones exhibited anxiolysis, and this effect was blocked by administration of flutamide. Flutamide also resulted in anxiolysis in the open-field box, suggesting the possibility of a nonlinear relationship between genomic effects of testosterone and anxiety.

In this study, administration of TP resulted in a concomitant increase in plasma levels of total testosterone in both prepubertal and aged mice compared to vehicle. The increase was significantly higher in aged mice compared to prepubertal mice; however, values obtained for prepubertal mice were significantly lower than values for mature noncastrated adult males (5.2 ng/mL) but higher than testosterone levels in age appropriate males (1.8 ± 0.9 ng/mL).[@b71-jen-10-2016-059] Generally, the serum testosterone levels for a male mouse typically range from 1.7 to 14.4 ng/mL with a mean of 6.78 ng/mL.

Conclusion
==========

Exogenous testosterone administration results in age-related neurobehavioral responses; however, more studies are needed to clarify the mechanisms that underlie them.
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![Effect of TP on body weight.\
**Notes:** Each bar represents mean ± SEM, number of animals per group (*n*) = 10; \**P* \< 0.05 vs VEH and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviation:** VEH, vehicle.](jen-10-2016-059f1){#f1-jen-10-2016-059}

![Effects of TP on open-field locomotor activity.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviation:** VEH, vehicle.](jen-10-2016-059f2){#f2-jen-10-2016-059}

![Effects of TP on rearing activity.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviation:** VEH, vehicle.](jen-10-2016-059f3){#f3-jen-10-2016-059}

![Effects of TP on grooming.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviation:** VEH, vehicle.](jen-10-2016-059f4){#f4-jen-10-2016-059}

![Effects of TP on radial-arm maze memory task.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH, ^+^*P* \< 0.05 vs SCOP, and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviations:** VEH, vehicle; SCOP, scopolamine.](jen-10-2016-059f5){#f5-jen-10-2016-059}

![Effects of TP on Y-maze memory task.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH, ^+^*P* \< 0.05 vs SCOP, and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviations:** VEH, vehicle; SCOP, scopolamine.](jen-10-2016-059f6){#f6-jen-10-2016-059}

![Effects of TP on anxiety behavior in the elevated plus maze.\
**Notes:** Each bar represents mean ± SEM, \**P* \< 0.05 vs VEH, ^+^*P* \< 0.05 vs DIZ, and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviations:** VEH, vehicle; DIZ, diazepam.](jen-10-2016-059f7){#f7-jen-10-2016-059}

![Effects of TP on Y-maze total arm entry.\
**Notes:** Each bar represents mean ± SEM, \**P* \< 0.05 vs VEH, ^\#^*P* \< 0.05 vs prepubertal vs aged, and ^+^*P* \< 0.05 vs SCOP.\
**Abbreviations:** VEH, vehicle; SCOP, scopolamine.](jen-10-2016-059f8){#f8-jen-10-2016-059}

![Effects of TP on radial-arm maze total arm entry.\
**Notes:** Each bar represents mean ± SEM, \**P* \< 0.05 vs VEH, ^\#^*P* \< 0.05 vs prepubertal vs aged, and ^+^*P* \< 0.05 vs SCOP.\
**Abbreviations:** VEH, vehicle; SCOP, scopolamine.](jen-10-2016-059f9){#f9-jen-10-2016-059}

![Effects of TP on percentage closed arm time.\
**Notes:** Each bar represents mean ± SEM, \**P* \< 0.05 vs VEH, ^\#^*P* \< 0.05 vs prepubertal vs aged, and ^+^*P* \< 0.05 vs DIZ.\
**Abbreviations:** VEH, vehicle; DIZ,diazepam.](jen-10-2016-059f10){#f10-jen-10-2016-059}

![Effects of TP on serum testosterone level.\
**Notes:** Each bar represents mean ± SEM; \**P* \< 0.05 vs VEH and ^\#^*P* \< 0.05 prepubertal vs aged.\
**Abbreviation:** VEH, vehicle.](jen-10-2016-059f11){#f11-jen-10-2016-059}
